Increasing Prevalence of Infectious Diseases to Augment the Point-of-Care (POC) Infectious Disease Diagnostics Market Growth
Point-of-care (POC) diagnosis includes sample testing to facilitate rapid diagnosis and decide on treatment planning accordingly. Infectious diseases often need to be diagnosed early, as they can be fatal against the immune system. POC infectious disease diagnostics allows early detection of diseases and can impact the medical outcome of treatment of the disease.
The U.S. FDA (United States Food and Drug Administration) is
responsible for overseeing all activities related to the marketing of diagnostic
products. POC diagnosis is cost-efficient and time saving, as well as offer various
benefits such as can be performed easily, prevent sample spillage, no necessity
of skilled professionals, etc.
Market Dynamics:
The emergence of COVID-19 (SARS-CoV-2) is expected to propel
the growth of the point-of-care (POC) infectious disease diagnostics market.
For instance, in February 2021, RNA Disease Diagnostics secured an exclusive
global license to a cutting-edge sensor technology jointly owned by the
University of Maryland, Baltimore County (UMBC) and the University of Maryland,
Baltimore (UMB). RNA Disease Diagnostics’ first product will be a rapid
point-of-care (POC) COVID-19 test with accuracy, sensitivity, and specificity
that is comparable to the gold standard RT-PCR lab diagnostic.
Moreover, initiatives and funding from government and
individual organizations for point-of-care (POC) infectious disease diagnostics
are expected to augment the growth of the point-of-care (POC) infectious
disease diagnostics market. For instance, in February 2021, Visby Medical
secured US$ 12.3 million from the United States Biomedical Advanced Research and
Development Authority to develop a next generation device to detect influenza
and COVID-19 in a single point-of-care rapid PCR test and, subsequently, as an
over-the-counter test for consumer use.
Increasing prevalence of infectious diseases in both developed
and developing countries and increasing incidence of target conditions is also
expected to fuel the growth of the point-of-care (POC) infectious disease diagnostics market. However, stringent and time-consuming regulatory policies
and pricing pressure due to reimbursement cuts and budget constraints are
expected to restrain the market growth.
Competitive Analysis:
Major players operating in the point-of-care (POC)
infectious disease diagnostics market are Cardinal Health, Inc., AccuBioTech
Co., Ltd., Trinity Biotech Plc., Thermo Fisher Scientific, Becton, Dickinson,
and Company, Hoffman-La Roche Ltd., Alcon Laboratories, Inc., Abbott
Laboratories, and Danaher Corporation.
Major players in the market are adopting various strategies,
such as merger, acquisition, and collaboration, to enhance their market
presence. For instance, in January 2021, Thermo Fisher Scientific announced a
definitive agreement to acquire molecular diagnostics company Mesa Biotech for
approximately US$ 450 million.
In September 2019, Abbott Laboratories and Sanofi collaborated
to integrate glucose sensing and insulin delivery technologies to further
simplify diabetes management.
Comments
Post a Comment